Prof. Liping Su 苏丽萍
Chief Physician, Professor
Department of Hematology, Shanxi Cancer Hospital, Taiyuan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Hematology, with a focus on the clinical diagnosis and treatment of malignant blood diseases.
Dr. Su is Chief Physician, Professor, and Department Director at Shanxi Cancer Hospital. Holding a doctoral degree, Dr. Su serves as a master’s supervisor and provincial academic leader. Research focuses on experimental basics, diagnosis, and treatment of malignant blood diseases. Dr. Su has led 11 national and provincial projects, received two first-class and two second-class Provincial Science and Technology Progress Awards, and co-authored six books.
Professional roles
- Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Vice Chair, Hematologic Oncology Professional Committee, Shanxi Anti-Cancer Association
- Standing Committee Member, Lymphoma Professional Committee, Shanxi Anti-Cancer Association
- Editorial Board Member, Journal of Leukemia & Lymphoma
Name order: in Chinese the family name comes first (Su Liping). Papers usually list the name as Liping Su or Su L.
Selected publications
73 papers on PubMed matched by name and affiliation; 18 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Correction to: Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study. PubMed 42634069
- JMIR Med Inform, 2026 (senior author): Integrated Clinical-Molecular Risk Stratification in Diffuse Large B-Cell Lymphoma: Machine Learning Survival Analysis. PubMed 42627678
- Front Oncol, 2026 (senior author): Efficacy, toxicity, and prognostic factors of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in elderly patients with diffuse large B-cell lymphoma: a single-center retrospective cohort study. PubMed 42052474
- Biomed Eng Online, 2026 (senior author): Prognostic value of BMI, prognostic nutritional index, and CRP in patients with lymphoma after autologous hematopoietic stem cell transplantation. PubMed 41820927
- Eur J Med Res, 2026 (senior author): XBP1-driven proliferative B cell subcluster in Diffuse Large B Cell Lymphoma linked to altered nucleotide metabolism. PubMed 41634749
- BMC Cancer, 2026 (senior author): Prognostic factors and nomogram development for adult diffuse large B-cell lymphoma: a single-center retrospective cohort study. PubMed 41629840
- JMIR Med Inform, 2026 (senior author): Automated Classification of Lymphoma Subtypes From Histopathological Images Using a U-Net Deep Learning Model: Comparative Evaluation Study. PubMed 41494052
- Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2025 (senior author): [The Epigenetic Regulation of Decitabine Resistance in TP53 -Mutated Myelodysplastic Syndromes: Integrated Analysis Based on RNA-seq and Methylomics]. PubMed 41502265
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion